{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T23:25:35Z","timestamp":1795217135263,"version":"4.10.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Swiss Center for Applied Human Toxicology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Scand J Trauma Resusc Emerg Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s13049-016-0299-z","type":"journal-article","created":{"date-parts":[[2016,9,2]],"date-time":"2016-09-02T16:06:47Z","timestamp":1472832407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Presentations to an urban emergency department in Switzerland due to acute \u03b3-hydroxybutyrate toxicity"],"prefix":"10.1186","volume":"24","author":[{"given":"Evangelia","family":"Liakoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian H.","family":"Nickel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"issue":"1","key":"299_CR1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1570159X13666141210215423","volume":"13","author":"FP Busardo","year":"2015","unstructured":"Busardo FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol. 2015;13(1):47\u201370.","journal-title":"Curr Neuropharmacol"},{"issue":"6","key":"299_CR2","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/15563650.2012.702218","volume":"50","author":"LJ Schep","year":"2012","unstructured":"Schep LJ, Knudsen K, Slaughter RJ, Vale JA, Megarbane B. The clinical toxicology of \u03b3-hydroxybutyrate, \u03b3-butyrolactone and 1,4-butanediol. Clin Toxicol (Phila). 2012;50(6):458\u201370.","journal-title":"Clin Toxicol (Phila)"},{"issue":"2","key":"299_CR3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1056\/NEJM200101113440202","volume":"344","author":"DL Zvosec","year":"2001","unstructured":"Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med. 2001;344(2):87\u201394.","journal-title":"N Engl J Med"},{"issue":"1","key":"299_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2165\/00139709-200423010-00002","volume":"23","author":"CG Wong","year":"2004","unstructured":"Wong CG, Chan KF, Gibson KM, Snead OC. Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug. Toxicol Rev. 2004;23(1):3\u201320.","journal-title":"Toxicol Rev"},{"issue":"5","key":"299_CR5","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1111\/bcp.12863","volume":"81","author":"ME Liechti","year":"2016","unstructured":"Liechti ME, Quednow BB, Liakoni E, Dornbierer D, von Rotz R, Gachet MS, et al. Pharmacokinetics and pharmacodynamics of \u03b3-hydroxybutyrate in healthy subjects. Br J Clin Pharmacol. 2016;81(5):980\u20138.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"299_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.drugalcdep.2005.07.010","volume":"81","author":"ME Liechti","year":"2006","unstructured":"Liechti ME, Kunz I, Greminger P, Speich R, Kupferschmidt H. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend. 2006;81(3):323\u20136.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"299_CR7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S0196-0644(98)70230-6","volume":"31","author":"RL Chin","year":"1998","unstructured":"Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of \u03b3-hydroxybutyrate overdose. Ann Emerg Med. 1998;31(6):716\u201322.","journal-title":"Ann Emerg Med"},{"issue":"4","key":"299_CR8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00265954","volume":"45","author":"P Palatini","year":"1993","unstructured":"Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol. 1993;45(4):353\u20136.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"299_CR9","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jat\/33.6.332","volume":"33","author":"AW Jones","year":"2009","unstructured":"Jones AW, Eklund A, Kronstrand R. Concentration-time profiles of gamma-hydroxybutyrate in blood after recreational doses are best described by zero-order rather than first-order kinetics. J Anal Toxicol. 2009;33(6):332\u20135.","journal-title":"J Anal Toxicol"},{"issue":"8","key":"299_CR10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jat\/28.8.625","volume":"28","author":"R Brenneisen","year":"2004","unstructured":"Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, et al. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol. 2004;28(8):625\u201330.","journal-title":"J Anal Toxicol"},{"issue":"4","key":"299_CR11","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/dta.1498","volume":"6","author":"A Schr\u00f6ck","year":"2014","unstructured":"Schr\u00f6ck A, Hari Y, K\u00f6nig S, Auw\u00e4rter V, Sch\u00fcrch S, Weinmann W. Pharmacokinetics of GHB and detection window in serum and urine after single uptake of a low dose of GBL: an experiment with two volunteers. Drug Test Anal. 2014;6(4):363\u20136.","journal-title":"Drug Test Anal"},{"key":"299_CR12","volume-title":"European Drug Report 2015: Trends and developments 2015","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2008","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2015: Trends and developments 2015. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2008. http:\/\/www.emcdda.europa.eu\/edr2015 . Accessed July 2016."},{"issue":"1","key":"299_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0376-8716(02)00017-0","volume":"67","author":"L Degenhardt","year":"2002","unstructured":"Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002;67(1):89\u201394.","journal-title":"Drug Alcohol Depend"},{"issue":"1-3","key":"299_CR14","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.drugalcdep.2007.07.009","volume":"92","author":"HR Sumnall","year":"2008","unstructured":"Sumnall HR, Woolfall K, Edwards S, Cole JC, Beynon CM. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend. 2008;92(1-3):286\u201390.","journal-title":"Drug Alcohol Depend"},{"key":"299_CR15","doi-asserted-by":"crossref","unstructured":"Dines AM, Wood DM, Yates C, Heyerdahl F, Hovda KE, Giraudon I, et al. Acute recreational drug and new psychoactive substance toxicity in Europe: 12\u00a0months data collection from the European Drug Emergencies Network (Euro-DEN). Clin Toxicol (Phila). 2015;53(9):893\u2013900.","DOI":"10.3109\/15563650.2015.1088157"},{"issue":"5","key":"299_CR16","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1080\/15563650701365818","volume":"45","author":"DK Sassenbroeck Van","year":"2007","unstructured":"Van Sassenbroeck DK, De Neve N, De Paepe P, Belpaire FM, Verstraete AG, Calle PA, et al. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila). 2007;45(5):533\u20138.","journal-title":"Clin Toxicol (Phila)"},{"issue":"8","key":"299_CR17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1399-6576.2010.02278.x","volume":"54","author":"K Knudsen","year":"2010","unstructured":"Knudsen K, Jonsson U, Abrahamsson J. Twenty-three deaths with \u03b3-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol Scand. 2010;54(8):987\u201392.","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"299_CR18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/jat\/28.6.481","volume":"28","author":"FJ Couper","year":"2004","unstructured":"Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol. 2004;28(6):481\u20134.","journal-title":"J Anal Toxicol"},{"issue":"6","key":"299_CR19","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/emj.2008.068403","volume":"28","author":"M Galicia","year":"2011","unstructured":"Galicia M, Nogue S, Miro O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J. 2011;28(6):462\u20136.","journal-title":"Emerg Med J"},{"issue":"2","key":"299_CR20","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1081\/CLT-120004400","volume":"40","author":"O Miro","year":"2002","unstructured":"Miro O, Nogue S, Espinosa G, To-Figueras J, Sanchez M. Trends in illicit drug emergencies: the emerging role of gamma-hydroxybutyrate. J Toxicol, Clin Toxicol. 2002;40(2):129\u201335.","journal-title":"J Toxicol, Clin Toxicol"},{"issue":"3","key":"299_CR21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/15563650701263633","volume":"46","author":"K Knudsen","year":"2008","unstructured":"Knudsen K, Greter J, Verdicchio M. High mortality rates among GHB abusers in Western Sweden. Clin Toxicol (Phila). 2008;46(3):187\u201392.","journal-title":"Clin Toxicol (Phila)"},{"issue":"1","key":"299_CR22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/qjmed\/hcm117","volume":"101","author":"DM Wood","year":"2008","unstructured":"Wood DM, Warren-Gash C, Ashraf T, Greene SL, Shather Z, Trivedy C, et al. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM. 2008;101(1):23\u20139.","journal-title":"QJM"},{"key":"299_CR23","doi-asserted-by":"crossref","unstructured":"Munir VL, Hutton JE, Harney JP, Buykx P, Weiland TJ, Dent AW. Gamma-hydroxybutyrate: a 30\u00a0month emergency department review. Emerg Med Australas. 2008;20(6):521\u201330.","DOI":"10.1111\/j.1742-6723.2008.01140.x"},{"issue":"11","key":"299_CR24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/acem.12516","volume":"21","author":"P Dietze","year":"2014","unstructured":"Dietze P, Horyniak D, Aqius P, Munir V, de Smit V, Johnston J, et al. Effect of intubation for gamma-hydroxybutyric acid overdose on emergency department length of stay and hospital admission. Acad Emerg Med. 2014;21(11):1226\u201331.","journal-title":"Acad Emerg Med"},{"key":"299_CR25","first-page":"w14166","volume":"145","author":"E Liakoni","year":"2015","unstructured":"Liakoni E, Dolder PC, Rentsch K, Liechti ME. Acute health problems due to recreational drug use in patients presenting to an urban emergency department in Switzerland. Swiss Med Wkly. 2015;145:w14166.","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"299_CR26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3109\/15563650.2014.898771","volume":"52","author":"DM Wood","year":"2014","unstructured":"Wood DM, Heyerdahl F, Yates CB, Dines AM, Giraudon I, Hovda KE, et al. The European Drug Emergencies Network (Euro-DEN). Clin Toxicol (Phila). 2014;52(4):239\u201341.","journal-title":"Clin Toxicol (Phila)"},{"issue":"3","key":"299_CR27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/15563659809028940","volume":"36","author":"HE Persson","year":"1998","unstructured":"Persson HE, Sjoberg GK, Haines JA, de Garbino Pronczuk J. Poisoning severity score: grading of acute poisoning. J Toxicol, Clin Toxicol. 1998;36(3):205\u201313.","journal-title":"J Toxicol, Clin Toxicol"},{"issue":"4","key":"299_CR28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.pra.0000452567.84825.07","volume":"20","author":"L Ghio","year":"2014","unstructured":"Ghio L, Cervetti A, Respino M, Belvederi Murri M, Amore M. Management and treatment of gamma butyrolactone withdrawal syndrome: a case report and review. J Psychiatr Pract. 2014;20(4):294\u2013300.","journal-title":"J Psychiatr Pract"},{"issue":"7-8","key":"299_CR29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/dta.292","volume":"3","author":"DM Wood","year":"2011","unstructured":"Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to \u03b3-hydroxybutyrate (GHB) and its analogues \u03b3-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal. 2011;3(7-8):417\u201325.","journal-title":"Drug Test Anal"},{"key":"299_CR30","doi-asserted-by":"publisher","unstructured":"White CM. Pharmacologic, pharmacokinetic, and clinical assessment of illicitly used \u03b3-hydroxybutyrate. J Clin Pharmacol. 2016; doi: 10.1002\/jcph.767 . Epub ahead of print.","DOI":"10.1002\/jcph.767"},{"issue":"3","key":"299_CR31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00414-008-0291-x","volume":"123","author":"S Djezzar","year":"2009","unstructured":"Djezzar S, Questel F, Burin E, Dally S. Chemical submission: results of 4-year French inquiry. Int J Legal Med. 2009;123(3):213\u20139.","journal-title":"Int J Legal Med"},{"key":"299_CR32","volume-title":"Sexual assaults facilitated by drugs and alcohol","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2008","unstructured":"European Monitoring Centre for Drugs and Drug Addiction. Sexual assaults facilitated by drugs and alcohol. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2008. http:\/\/www.emcdda.europa.eu\/publications\/technical-datasheets\/dfsa . Accessed July 2016."},{"issue":"3","key":"299_CR33","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.ajem.2009.11.008","volume":"29","author":"DL Zvosec","year":"2011","unstructured":"Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 \u03b3-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med. 2011;29(3):319\u201332.","journal-title":"Am J Emerg Med"},{"key":"299_CR34","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1196\/annals.1369.065","volume":"1074","author":"S Abanades","year":"2006","unstructured":"Abanades S, Farre M, Segura M, Pichini S, Barral D, Pacifici R, et al. \u03b3-Hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann N Y Acad Sci. 2006;1074:559\u201376.","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"299_CR35","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/00007691-200408000-00014","volume":"26","author":"SP Elliott","year":"2004","unstructured":"Elliott SP. Nonfatal instances of intoxication with \u03b3-hydroxybutyrate in the United Kingdom. Ther Drug Monit. 2004;26(4):432\u201340.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"299_CR36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1067\/mem.2003.253","volume":"42","author":"KA Sporer","year":"2003","unstructured":"Sporer KA, Chin RL, Dyer JE, Lamb R. \u03b3-Hydroxybutyrate serum levels and clinical syndrome after severe overdose. Ann Emerg Med. 2003;42(1):3\u20138.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"299_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00414-008-0299-2","volume":"124","author":"FC Kugelberg","year":"2010","unstructured":"Kugelberg FC, Holmgren A, Eklund A, Jones AW. Forensic toxicology findings in deaths involving gamma-hydroxybutyrate. Int J Legal Med. 2010;124(1):1\u20136.","journal-title":"Int J Legal Med"},{"key":"299_CR38","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neubiorev.2015.03.012","volume":"53","author":"JM Corkery","year":"2015","unstructured":"Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, et al. Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): a literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev. 2015;53:52\u201378.","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13049-016-0299-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T21:53:29Z","timestamp":1498341209000},"score":1,"resource":{"primary":{"URL":"http:\/\/sjtrem.biomedcentral.com\/articles\/10.1186\/s13049-016-0299-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["299"],"URL":"https:\/\/doi.org\/10.1186\/s13049-016-0299-z","relation":{},"ISSN":["1757-7241"],"issn-type":[{"value":"1757-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]},"article-number":"107"}}